The Pharma Data

JUNE 18, 2021

After one year, 47 percent of patients receiving risankizumab 360 mg achieved endoscopic response compared with 22 percent of patients in the induction-only control group (p<0.001). analysis plan), with 52 percent on risankizumab 360 mg achieving clinical remission versus 41 percent in the induction-only control group (p<0.01).

Trials 40

Trials Development Clinical Trials Clinical Trials 40

The Pharma Data

FEBRUARY 22, 2021

AbbVie (NYSE: ABBV) today announced that upadacitinib (45 mg, once daily) met the primary endpoint of clinical remission (per Adapted Mayo Score) and all ranked secondary endpoints in the Phase 3 induction study, U-ACCOMPLISH. All primary and ranked secondary endpoints achieved p-values of <0.001 versus placebo.

Medicine 52

Medicine Development Drugs Trials 52

The Pharma Data

JUNE 18, 2021

All differences between the overall risankizumab dose groups and placebo are statistically significant, with p-values <0.001. Risankizumab (SKYRIZI) is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally. About AbbVie in Gastroenterology.

Clinical Trials 40

Clinical Trials Clinical Trials Trials Development 40

The Pharma Data

JUNE 18, 2021

vice president and head, global oncology development, AbbVie. VENCLYXTO/VENCLEXTA is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S. 1.35]; P=0.49). VENCLYXTO is being developed by AbbVie and Roche.

Medicine 40

Medicine HR Trials Production 40

The Pharma Data

JUNE 18, 2021

This rate was higher than the 37% minimum meaningful rate study assumption (P<0.0001). “Combining our novel therapies to deliver a new potential treatment is an example of AbbVie’s innovative approach to identify options for difficult-to-treat blood cancers, like CLL,” said Mohamed Zaki , M.D., NORTH CHICAGO, Ill.

Medicine 40

Medicine Production FDA Approval Trials 40

The Pharma Data

JUNE 18, 2021

The study met its primary endpoint of superior progression-free survival (PFS) as assessed by an independent review committee (IRC) with a HR 0.216 (95% CI, 0.131-0.357; p < 0.0001), demonstrating a reduction in the risk of disease progression or death for I+V of approximately 78% compared to C+O. vs. 11.4%) (p < 0.0001).

Medicine 52

Medicine Production FDA Approval Trials 52

The Pharma Data

JUNE 18, 2021

June 4, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV), today announced extended long-term data from the Phase 3 RESONATE-2 study ( PCYC-1115/1116 ) evaluating single-agent IMBRUVICA (ibrutinib) versus chlorambucil with up to seven years of follow-up in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

FDA Approval 40

FDA Approval Medicine Development Trials 40